BioSpace is proud to present its NextGen Bio “Class of 2019,” a list of 20 up-and-coming life science companies in North America that launched* no earlier than 2017.
The NextGen Bio Class of 2019 is a stellar group of companies that are already making an enormous impact on the industry now and will continue into the future. Congratulations to this group!
Skyhawk Therapeutics
Points: 17
Launched: 2018
Location: Waltham, MA
Notable:
In June 2018, Skyhawk Therapeutics closed a $40 million equity investment round and then, in an unusual deal, signed a five-year collaborative agreement with Celgene that included an upfront $60 million.
Skyhawk focuses on developing small molecule therapeutics that correct RNA mis-splicing, what is usually called exon skipping.
The company expects to move its first oncology treatment into the clinic in 2019.
Skyhawk currently has four targets in oncology and three in neuro, which are in lead selection but past preclinical IND filing.
For more information visit:
SKYHAWK MEDIA CONTACT:
Maura McCarthy
Comments